Here are five things to know.
1. The investigation, which began during the Obama administration in 2014, has since spread to nearly every major generic drugmaker, including Teva Pharmaceuticals and Mylan.
2. People familiar with the matter told Bloomberg that two companies and several executives are slated to be indicted and a third company may agree to plead guilty before the charges emerge.
3. The looming charges involve allegations of price-fixing and dividing up the market to make higher profits.
4. Throughout the investigation, the FBI has raided at least two companies, including Perrigo in 2017 and Mylan in 2016.
5. Prosecutors haven’t announced any developments in the case and no charges have been disclosed since two former executives of Heritage Pharmaceuticals were charged with collusion in December 2016. Both executives pled guilty and avoided fighting the charges.
More articles on supply chain:
‘Convoluted’ and ‘expensive’ among US employers’ most common descriptors for the drug supply chain
Mylan eliminates more than 400 positions at West Virginia plant: 3 notes
Safety violations at PharMEDium worsen hospital painkiller shortage
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.